Tweets by IDWeek 2023

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Presentation Icons

Live Streamed

On Demand

538 Views

150. HIV: Treatment: Friday, 12:15 - 1:30 p.m.

Poster Session: HIV: Treatment

(1561) Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) Versus Dolutegravir (DTG)‑Based 3-Drug Regimens in Adults With HIV Who Have Suboptimal Antiretroviral Adherence

Friday, October 13, 2023

12:15 PM – 1:30 PM US ET

Location: Hall B + C

Presenting Author(s)

Kristen Andreatta, MS

Research Scientist
Gilead Sciences, Inc.
Foster City, CA, United States

PS

Paul E. Sax, MD

Brigham and Women’s Hospital, Harvard Medical School
Boston, Massachusetts, United States
David Alain Wohl, MD

Professor of Medicine
UNC School of Medicine
Chapel Hill, NC, United States
MD

Michelle L. D’Antoni, PhD

Gilead Sciences, Inc.
Foster City, California, United States
HH

Hailin Huang, PhD

Gilead Sciences, Inc.
Foster City, California, United States
JH

Jason Hindman, PharmD, MBA

Gilead Sciences
Foster City, California, United States
CC

Christian Callebaut, PhD

Gilead Sciences
Foster City, California, United States
HM

Hal Martin, MD

Exec Director, Virology Clinical Research
Gilead Sciences
Foster City, California, United States